drugset / Trial / NCT00645177

Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer

NCT00645177

Phase 2 Completed 10 enrolled AbbVie Genentech, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the effect of ABT-869 plus paclitaxel compared to paclitaxel alone on disease progression in metastatic breast cancer.

Timeline

Start
2008-07
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator ABT-869 Unknown 0.2 mg/kg Oral
Comparator Paclitaxel Small molecule 90 mg/m2 Intravenous

Indications